Abcuro

Breakthrough Therapies for Autoimmune Diseases & Cancer

Home

Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease

news

Abcuro Announces Participation in Upcoming Investor Conferences

Newton, Massachusetts, November 11, 2024— Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences. Stifel 2024 Healthcare Conference: Presentation on November 18, 2024, at 3:00 pm

 READ MORE

READ MORE
November 11, 2024
Abcuro Announces Participation in Upcoming Investor ConferencesPress Releases

Targeting Highly Cytotoxic T Cells

Highly cytotoxic T cells have been implicated as mediators of tissue damage in many autoimmune diseases

 

ABC008 in Autoimmune Disorders

ABC008, an investigational monoclonal antibody, selectively depletes highly cytotoxic T cells

 

Inclusion Body Myositis

Inclusion body myositis (IBM) is a debilitating chronic, progressive disorder in which muscle is destroyed by highly cytotoxic T cells

 

Privacy Site Credits Terms of Use

© 2025 Abcuro